Introduction {#s1}
============

Rationale and Objectives {#s1_1}
------------------------

Neuropsychiatric diseases are a leading cause of disability worldwide, with numbers expected to increase dramatically in the coming decades, mainly due to aging populations ([@B4]). Possibly the most incapacitating of these illnesses is dementia---causing substantial physical and psychological disability, suffering, dependency, and economic costs for patients, caregivers, and society alike ([@B50]). Several potentially disease-modifying drug trials may have failed because a disease like Alzheimer's (AD) is usually diagnosed clinically after underlying pathological processes have already been going on for years, or even decades ([@B38]; [@B40]; [@B61]). This, in turn, has led to a major interest in possible prodromal or (modifiable) risk factors for the development of dementia ([@B8]). Even though most forms of dementia are currently incurable, it has been hypothesized that a 10% reduction of known risk factors could result in a global decrease of more than one million future cases of dementia ([@B5]).

Depressive symptoms have been linked to dementia. Indeed, clinicians have long acknowledged that depression in the elderly can mimic dementia in a situation known as depressive *pseudodementia* ([@B1]). However, depressive symptoms may also be the first clinical manifestation of incipient dementia. Indeed, behavioral and psychological symptoms, such as depression, are highly prevalent in patients with dementia, leading to overlap in clinical presentations of cognitive impairment in the elderly ([@B65]). Others have suggested that depression and dementia share common risk factors and thereby frequently occur together without being causally linked themselves ([@B27]), or that psychological symptoms may occur (merely) as a reaction to incipient decline in patients who are aware of their cognitive disturbances. Another explication uses the "cognitive reserve" paradigm. This idea posits that intercurrent (physical or mental) illness in an already diseased and/or aged brain will lower the threshold for experiencing cognitive problems and therefore cause symptoms of the same pathophysiological process to manifest earlier ([@B68]). Multiple studies designed to assess risk and causality have provided conflicting results ([@B10]).

Depression in the elderly is more often associated with cognitive symptoms as compared to depressive disorders of earlier adulthood ([@B44]). On the other hand, depression itself may actually cause cognitive decline---conceivably related to certain pathophysiological processes of, for example, frontal and hippocampal atrophy possibly through glutamatergic or steroid-related toxicity ([@B60]; [@B16]; [@B69]). Still other studies have pointed out that even early-life depressive episodes increase the risk of later dementia ([@B24]; [@B66]). The aforementioned possibilities are, of course, not mutually exclusive and quite possibly overlap in everyday clinical situations.

It is clear that the association between late-life depression and dementia is complex. To shed further light upon this issue, we conducted this systematic literature review. It focuses on the relationship between depressive symptoms that develop late in life and the subsequent development of dementia in general.

We acknowledge that depression (as in major depressive disorder) and depressive symptoms are not interchangeable terms. Identifying significant depressive symptoms, rather than limiting studies to those restricting themselves to clinician-ascertained major depressive episode alone, however, will broaden the scope of this review and include more large-scale epidemiological studies. Clinicians, also, will recognize the importance of depressive (and other neuropsychiatric) symptoms that are not severe enough to lead to a formal syndromal diagnosis. A similar rationale was used to examine dementia in a broad sense. Although AD is the most common and best studied form of dementia, vascular and mixed etiologies will not be excluded from our review as they contribute significantly to the aforementioned epidemiological and clinical problems ([@B4]; [@B50]). Assessing the studies obtained will help identify the gaps in our knowledge that may guide specific future research.

Methods {#s2}
=======

Research Question {#s2_1}
-----------------

To define our research question, we used the Patient/Problem/Population, Intervention, Comparator, Outcome or PICO paradigm---a well-acknowledged framework for framing healthcare and evidence questions, as well as a useful tool to develop concrete questions in complicated and multifactorial issues such as the one we set out to examine. Through a systematic literature review, we studied "whether depressive symptoms (I) in cognitively intact older adults (P) are associated with a diagnosis of dementia later in life (O), diagnosed using validated biomarkers or criteria, as compared to nondepressed matched controls (C)."

Design and Protocol {#s2_2}
-------------------

Using PRISMA as guidance ([@B54]), we included human longitudinal, prospective cohort studies reporting on a possible link between depression and depressive symptoms in the elderly (older than 65 years of age) and later development of dementia (not merely cognitive decline in a broader sense) in statistical, and not merely narrative, terms. We did not include case series or other designs to minimize bias, as prospective studies are acknowledged to be less vulnerable to certain forms of bias when ascertaining hazard and risk relationships, especially over longer periods of time. Comparator groups were defined as matched elderly subjects without depressive symptoms. We included memory clinic as well as general community-based population studies of the aforementioned types. No specific length of follow-up was required. There were no restrictions on diagnostic criteria nor rating scales used for detection of depression or dementia, as long as they were clearly defined and respected. We excluded studies ascertaining similar problems in highly specific pathological situations, such as Huntington's disease, Down syndrome, or prion diseases. No language or publication date restrictions were applied.

Medline and PsycINFO databases were searched in November 2018 using combinations of the following terms we identified through the PICO paradigm: depression (including variant wordings such as "depressive symptoms" in MeSH), dementia, Alzheimer, elderly, incidence, risk, hazard, cohort. We subsequently added search terms containing clinical diagnostic biomarkers such as magnetic resonance imaging (MRI), positron emission tomography (PET), cerebrospinal fluid (CSF), biomarkers, amyloid, tau, and neuropsychological test/examination (see [**Supplementary Material Table**](#SM1){ref-type="supplementary-material"} for these keywords and combinations used).

We collected and deduplicated references using EndNote software (*Clarivate Analytics*). Titles and abstracts were screened by carefully excluding publications irrelevant to our research question (mainly *in vitro* studies, cross-sectional designs, papers about highly specific other illnesses as mentioned above, case studies...---i.e., publications clearly incompatible with our inclusion criteria and research question). Studies with possibly relevant contents were fully read and considered for inclusion using the aforementioned inclusion and exclusion criteria and preparing to resolve possible conflicts on study inclusion or exclusion (which did not occur) among the three authors by consensus. We further screened the references of these articles for missed relevant publications. All were evaluated for possible objective errors. No studies found through PsycINFO were unlisted in Medline searches. As such, all (n = ...) refer to references obtained from Medline. We used the Newcastle--Ottawa Scale (NOS) for cohort studies to assess risk of bias (obtained from ohri.ca/programs/clinical_epidemiology/oxford.asp) in prospective cohort studies.

Results {#s3}
=======

Results are listed in [**Figure 1**](#f1){ref-type="fig"}. Out of 1,656 search results, 1,601 titles and abstracts were excluded as clearly irrelevant. Fifty-five full articles were read and evaluated, of which 27 were excluded according to our predefined inclusion criteria. In our final assessment, 31 studies were included. We briefly mention seven additional publications that looked at cognitive decline *sensu lato* rather than dementia and five studies that included many patients deemed too young as per our cutoff of 65 years. Three papers by Wilson et al. ([@B75]; [@B77]; [@B78]) described similar cohorts and neuropathological data and were merged into one additional reference. One additional study was added through follow-up for publication of an earlier abstract of interest the authors read at a conference ([@B28]). Two other papers were included from paper references. No data were extracted as we considered the obtained papers to be too heterogeneous to perform meta-analysis.

![Selection of studies included in this systematic review.](fphar-11-00034-g001){#f1}

We grouped these references in five categories for review purposes---noting that their main conclusions are not mutually exclusive and many authors, indeed, suggest multiple explanations for their findings. Critical assessment of the papers' numerical results as well as their authors' main interpretation thereof in the respective discussion sections was used to classify the references in our different categories, as discussed further in this section. Additional substantiation is provided in the [**Supplementary Material**](#SM1){ref-type="supplementary-material"}.

A.  Studies suggesting that depression is a risk factor for dementia A1 (n = 7) and studies suggesting that depression is not a risk factor for dementia or that they are linked without reaching statistical significance A2 (n = 8)

B.  Studies that suggest that depression is an early symptom or prodrome of dementia (n = 10)

C.  Studies that suggest that depression is both an early symptom and a risk factor (n = 1)

D.  Studies demonstrating an association between depression and dementia, without clear conclusions concerning potential causality \[n = 3 (one reference for three related papers)\]

Results are listed by their aforementioned category in [**Tables 1**](#T1){ref-type="table"}--[**4**](#T4){ref-type="table"} (listing A1, A2, B, C&D).

###### 

(Category A1): Studies suggesting that depression is a significant risk factor for dementia.

  Study      Cohort                                                      N                                                 Mean age (SD)   \% Female   FU                                                    Depression assessment                               Diagnostic criteria of cognitive decline   Incidence of dementia                                             Risk?                                                                            Risk adjustments
  ---------- ----------------------------------------------------------- ------------------------------------------------- --------------- ----------- ----------------------------------------------------- --------------------------------------------------- ------------------------------------------ ----------------------------------------------------------------- -------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------
  ([@B14])   Community of English speaking Australians                   799 (480 NC, 319 MCI). 169 drop-outs              78 (4.7)        67.8%       2 years                                               NPI                                                 Petersen MCI, DSM-IV Dementia              11 from MCI, 3 from NCI, too small for subtyping                  OR 3.67 \[1.1--12.5\]                                                            No difference (age, sex, education, NPI score)
  ([@B15])   Prospective UDS NACC: 80% White, 13% African, 6% Hispanic   11453 start, 8762 more than 1 visit               71 (10.89)      65.2%       Mean 3 years (1-10)                                   1\) Recent 2) Earlier 3) Current episode (DSM-IV)   AD NINCDS/ADRDA                            330 AD. Subgroups not clearly reported                            1\) HR 2.35 \[1.88--2.94\] 2) HR 1.35 \[1.06--1.73\] 3) HR 2.82 \[2.21--3.59\]   Stronger after correction 1) HR 5.75 \[3.28--10.07\] 2) 3.20 \[1.78--5.73\] 3) HR 5.50 \[3.09--9.64\]
  ([@B22])   Community in Manhattan 30% White, 41% Latino 27% African    852 NC at baseline, 478 one or more FU sessions   73 (7.1)        69.4%       1-5, mean 2.54 years (1.12 SD)                        HAM-D \>10 and 'mood' item                          DSM-III-R                                  61 cases, (21% depressed vs 9% non), mostly AD (2 other, 1 PSP)   RR 2.94 \[1.7-4.9\]                                                              Still significant (RR 2.05) after age, education, Moderate CI
  ([@B28])   Einstein Aging study: Bronx community, 65% white            1219                                              78 (5.4) 70+    62%         Yearly visits for 4.5 years (3.5 SD) up to 17 years   GDS-15                                              DSM-IV                                     132 cases, 111 AD                                                 Per point HR 1.11 \[1.03-1.19\], not significant before 3 years                  Age, sex, race, education, comorbidity and baseline cognition (BIMC)
  ([@B37])   USA Japanese in Hawaii                                      1932                                              76 (3.6)        0%          6.1 years mean                                        CES-D \> 9                                          DSM-III-R, NINCDS/ADRDA                    6.3% (e4), 9.3% (dep) 13.7% (both) 4.2%(neither)                  Dementia HR 2.2 \[1.3--3.7\] AD 2.9 \[1.4--5.9\]                                 Classic risk factors and self-reported memory
  ([@B64])   Framingham study: prospective community cohort              949                                               79 (5)          63.6%       Mean 8, up to 17 years                                CES-D \> 16                                         DSM-IV, CDR \>1, NINCDS/ADRDA              164 cases (136 AD)                                                Dementia HR 1.72 \[1.04--2.84\] AD 1.76 \[1.03--3.01\]                           Age, education, homocysteine, APOE, MCI
  ([@B67])   Oldest old white (SOF WISE)                                 302                                               87 (2) \> 85    100%        5 years after baseline                                GDS-15 \> 6                                         Petersen MCI, DSM-IV-TR dementia           84 cases 65% of GDS ≥6 & 37% \< 6                                 MOR 3.15, \[1.03-9.65\]                                                          Risk factors, alcohol, benzodiazepines

Values in square brackets are 95% confidence intervals. p-values are under 0.05 unless otherwise specified. UDS-NACC, Uniform Data Set - National Alzheimer's Coordinating Centre; NC, Normal cognition; MCI, Mild Cognitive Impairment; SD, Standard Deviation; GDS, Geriatric Depression Scale; HAM-D, Hamilton Depression Rating Scale; NPI, Neuropsychiatric Inventory; DSM, Diagnostic and Statistical Manual of Mental Disorders (American Psychiatric Association); FU, follow-up, NINCDS; National Institute of Neurological and Communication Disorders and Stroke; ADRDA, Alzheimer's Disease and Related Disorders Association criteria; CES-D, Centre for Epidemiological Studies Depression scale; BIMC, Blessed Information Memory Concentration; CDR, Clinical Dementia Rating Scale; SOF-WISE, Study of Osteoporotic Fractures - Women; Cognitive Impairment Study of Exceptional Aging.

###### 

(Category A2): Studies not suggesting that depression is a significant risk factor for dementia.

  Study      Cohort                                      N                                        Mean age (SD)                    \% Female                            FU                            Depression assessment                             Diagnostic criteria of cognitive decline   Incidence of dementia                   Risk?                                             Adjustments
  ---------- ------------------------------------------- ---------------------------------------- -------------------------------- ------------------------------------ ----------------------------- ------------------------------------------------- ------------------------------------------ --------------------------------------- ------------------------------------------------- -------------------------------------------------
  ([@B9])    CHS-CS Pittsburgh community                 288                                      78 (3.65)                        63%                                  7.1 years (1--9)              CES-D \>10                                        3MSE, DSM-IV, NINCDS/ADRDA                 48, all AD                              None found                                        All kinds of risk factors in CHS study
  ([@B11])   VITA -- 2 Vienna districts                  331 never depressed undemented           76 (0.5)                         56.5%                                0 -- 2.5 -- 5 years           DSM-IV, sGDS                                      NINCDS/ADRDA                               33                                      Serum Ab42, male gender, age were risks           Multivariate logistic regression analyses
  ([@B34])   Rotterdam population Scan Study             486                                      74 (6.5)                         49%                                  5.9 years (1.5 SD)            Interview-based (early vs. late (60y)) CES-D 16   CAMDEX and standard criteria               33 AD                                   EARLY history of depression risk factor           MRI volumetrics and WML
  ([@B43])   Korean community survey                     518                                      72 (5) 65+                       54.4%                                2.4 years                     Korean GDS                                        Standard criteria                          45 (34 AD, 7 VaD, 4 other)              Strong risk of dep + APOE men (cf. Irie)          Vascular risk factors, APOE
  ([@B49])   Prospective Canadian Health & Aging study   4609                                     Cases 87 Controls 78 (70--100)   58%                                  5 years after initial visit   DSM-III-R (no symptoms only)!                     NINCDS-ADRDA, DSM-III, NINDS-AIDEN         194 AD, 527 MCI and 'other' dementias   Age, education, APOE                              Reduction by wine, coffee, NSAIDs, exercise,...
  ([@B55])   VITA -- 2 Vienna districts                  437 (296 at 60 months) never depressed   76 (0.5)                         55%                                  60 months                     DSM-IV-TR questionnaire, HDRS, sGDS               NINCDS-ADRDA                               65 (AD)                                 OR 5.27 \[1.62-17.2\] for loss of interest only   Risk factors, biochemical parameters, APOE
  ([@B57])   Gothenburg census of 85 year olds           227 healthy and 62 depressed             85 years old at baseline         Not explicitly stated in subgroups   3 years                       DSM-III-R, history and records                    Not clearly stated, MMSE                   50 cases                                Only early onset MDD                              CT volumetrics
  ([@B74])   Leiden (NL) 85 year olds                    500 (298 4^th^ year)                     85 years old at baseline         63%                                  Yearly for 4 years            GDS-15                                            MMSE, Stroop, LDCT, 12 Word Recall         Not explicitly stated                   Correlation but no risk of decline                Mixed models

3MSE, Modified Mini Mental State Examination; WML, White Matter Lesions; AIDEN, Association Internationale pour la Recherche et l'Enseignement en Neurosciences; MDD, Major Depressive Disorder; LDCT, Letter Digit Coding Test.

###### 

(Category B): Studies suggesting that depression is a prodromal symptom of dementia.

  Study      Cohort                                      N                       Mean age (SD)        \% Female         FU                                       Depression assessment                           Criteria for cognitive decline               Incidence                                   Risk?                                                                     Adjustments
  ---------- ------------------------------------------- ----------------------- -------------------- ----------------- ---------------------------------------- ----------------------------------------------- -------------------------------------------- ------------------------------------------- ------------------------------------------------------------------------- ---------------------------------------------------------------------
  ([@B3])    Health in Men (Western Australia)           4922                    77 (3.7) 71-89       0%                8.9 mean, up to 14 years                 sGDS-15, history, health record                 Healthcare records coding                    903 cases (18%)                             aSHR: Ever 1.3 \[1.2-1.7\] Past 1.3 \[1.0-1.6\] Current 1.5 \[1.2-2.0\]   Antidepressant use, stroke, risk factors. ONLY in the first 5 years
  ([@B18])   MoVIES cohort USA 97% white                 954                     65-85                54.6%             8 years with 2 yearly intervals          mCES-D                                          NINCDS-ADRDA, DSM-III, CERAD                 78 (61 AD)                                  'Reverse' risk                                                            Age, sex, education, self-reported cogn.
  ([@B29])   Aquitaine France community                  3777 (1500 at year 8)   75 (7) 65+           58.3%             8 years (1, 3, 5, 8)                     CES-D (men 17 women 23)!                        NINCDS-ADRDA, DSM-III-R, Hachinski           280 cases (200 AD)                          OR men 3.5 \[1.9--6.5\] Women \[1.2 0.7--2.0\]                            Hypertension in men 50% additional risk
  ([@B31])   Manitoba Canada Community                   766                     75 (6) 65+           61.7%             5 years                                  CES-D (\> 16 and other values)                  Standard Criteria                            56 (36 AD)                                  AD OR 2.75 \[1.04--7.24\] Dementia 2.37 \[1.02--5.54)                     Not earlier reported depression, not duration of symptoms
  ([@B33])   Two Netherlands cohorts                     1911 + 1894             73 (5) and 70 (8)    62.3% and 52.9%   4 years                                  GMSS and CES-D respectively                     "3 point MMSE drop" and criteria             53 AD AMSTEL                                aOR \>8y educated 5.3 \[1.8-15\]                                          Age, gender, education, psychiatric
  ([@B47])   Three French Cities (3C Study)              7989                    74 (5) 65+           61%               2 times 2 years                          MDE-MINI (DSM IV), CES-D                        NINCDS-ADRDA, DSM-IV, Hachinski, AIREN       180 AD, 24 Vasc Dem, 29 mixed, 43 various   Dementia HR 1.5 \[1.2--2.2\] Vascular 4.8 \[2.2--10.7                     Risk factors and age, MRI WML, not earlier episodes
  ([@B48])   Seattle ACT study                           3410                    75 (6) 65+           60%               7.1 average, Biennially up to 15 years   CES-D-11, history of past episodes              CASI, DSM-IV, NINCDS-ADRDA                   658: 386 AD, 89 Vasc, 113 mix, 70 other     All cause aHR 1.61 \[1.29- 2.01\]                                         Age, gender, education, baseline CASI
  ([@B53])   Rotterdam community scan study              3325                    74.88 (IQR 71--80)   60%               3 times in 10 years                      CES-D, HADS-D -- 3 trajectories!                MMSE, GMS, CAMDEX, DSM-III-R, NINCDS-ADRDA   434 dementia -- 348 AD, 26 Vasc, 60 other   Increasing trajectory dementia HR 1.42 \[1·05--1·94\]                     Age, sex, *APOE*, education, medication, risk factors, cognition
  ([@B58])   Stockholm community-based                   185 (+47 MCI)           84 (5) 75-95 years   84.9%             3.4 years (0.6 SD)                       Comprehensive Psychopathological Rating Scale   DSM-III-R, NINCDS-ADRDA                      10 AD 7 dementia in healthy                 AD RR 1.9 \[1.0-3.6\] per mood symptom                                    Corrected for age, sex, education. Anxiety in MCI
  ([@B73])   LADIS study of WML (clinic finding based)   639                     74.1 +- 5y           55%               3 times annually                         sGDS                                            NINCDS-ADRDA/AIREN                           34 AD, 54 VD, 2 FTLD                        GDS HR 2.4 \[1.4 3.99\]                                                   Risk factors. Previous depression not significant

aSHR, Adjusted sub-hazard ratio; CERAD, Consortium to Establish a Registry for Alzheimer's Disease; GMSS, Geriatric Mental State Schedule; MDE-MINI, Major Depressive Disorder part of the Mini International Neuropsychiatric Interview; CASI, Cognitive Abilities Screening Instrument; IQR, Interquartile Range; WML, White Matter Lesions.

###### 

(Categories C & D): Studies suggesting both or neither.

  Study                      Cohort                          N               Mean age (SD)                 \% Female   FU                             Depression assessment         Diagnostic criteria of cognitive decline       Incidence                                 Risk?                                                          Adjustments
  -------------------------- ------------------------------- --------------- ----------------------------- ----------- ------------------------------ ----------------------------- ---------------------------------------------- ----------------------------------------- -------------------------------------------------------------- -------------------------------------------
  ([@B30])                   MoVIESBlue-collar rural U.S.A   1265            75 (5)                        60.8%       Biannually for 12 years        mCES-D                        CERAD, DSM-III-R                               171 cases of dementia                     Multiple interaction models finding no long-term association   Classic risk factors
  ([@B42])                   HABC Study, mixed USA           2488            74 (2.4)                      53%         4 years                        CES-D-10 and 'trajectories'   Records, medication, MMS decline               353 cases of dementia                     High and increasing trajectory                                 Demographic and health factors, cognition
  ([@B51])                   LEILA 75+ Study                 1265            75 years and older, mean 81   73%         Every 1.5 years over 8 years   CES-D                         SIDAM - DSM IV                                 183 cases of dementia                     Only for MD in multivariate                                    Classic risk factors
  ([@B75]; [@B77]; [@B78])   Different prospective cohorts   130/1750/1965   76 (7.5) in 3rd study         73.8%       Differing per cohort/paper     CES-D                         DSM-III, NINCDS-ADRDA, Pathological criteria   346 cases of dementia in largest cohort   Cfr. text discussion.                                          Cfr. text discussion.

SIDAM, Structured Interview for Diagnosis of Dementia of Alzheimer type, Multiinfarct Dementia and Dementia of other Aetiology; MD, Major Depression.

Bias assessment using the NOS did not show any systematic difference in biases between categories, with all studies scoring relatively high on this design quality scale. We therefore conclude this had little influence on our findings. Results and additional comments are available in the [**Supplementary Material Table**](#SM1){ref-type="supplementary-material"}.

These studies propose that depressive symptoms confer an additional risk of a future development of dementia in cognitively healthy elderly individuals. This view has to be contrasted with the hypothesis that psychological symptoms simply accentuate or temporarily cause cognitive deficits, thereby accounting for that proportion of mild cognitive impairment (MCI) patients who do not "convert" to dementia but rather recover a normal cognitive status ([@B45]). Some studies ([@B37]; [@B28]) indeed corrected for baseline emotional and cognitive scores to address this possibility. We did not include studies evaluating the link between early-life (onset before 65 years of age) depression and later dementia, even though this could be of interest to our research question; indeed, other review efforts appear to suggest this link ([@B56]). Interestingly, several studies, including the largest one ([@B15]) in this category, suggest that dementia risk in people with depressive symptoms increases further when corrected for classically biasing factors such as age, education, or socioeconomic status, thus providing an argument against the position that depressive symptoms and dementia are linked solely through common risk factors and justifying classification in category A1. This relation becomes even stronger when associated with certain *APOE* genotypes, a well-known genetic risk factor for AD---a finding also reported by smaller samples ([@B37]; [@B43]).

Considering some of the proposed pathophysiological mechanisms (chronic inflammation, glucocorticoid toxicity, neuronal energetic dysregulation, etc.), a true biological risk relationship would imply that more severe and/or long-standing depression increases one's chance of cognitive deterioration due to a neurodegenerative or cerebrovascular brain disease. Although some reports ([@B75]; [@B31]; [@B64]; [@B45]) have shown such a link, most studies use depressive symptoms as a binary value (depressed--not depressed) and/or contain too many individuals with mild depressive symptoms to really establish a "dose--response" relationship of this kind. Furthermore, most studies did not evaluate these proposed mechanisms (e.g., through blood or CSF analysis, functional or advanced imaging). It is etiologically difficult to disentangle depression being a pure risk factor or an actual prodromal symptom of dementia, especially during the 2- or 3-year follow-up of most studies. However, some studies followed patients for up to 17 years and reported similar findings ([@B64]). One strong argument for the true risk hypothesis would be clinical trials indicating that successful treatment of major depressive episodes lowers the incidence of (solidly diagnosed) degenerative dementia. This is a controversial question, with multiple studies of different (mainly pharmacological) treatments providing conflicting results ([@B46]; [@B39]; [@B3]; [@B19]; [@B12]). We further note that the successful treatment of clinical depression is a challenge in itself, as only one in three patients respond to first-line treatments and as many remain treatment resistant after multiple treatments, a situation that may be even more frequent in the elderly ([@B63]). Interestingly, some authors have even suggested that anti-amyloid therapies may have a role to play in treating late-life depressive syndromes ([@B52]). Nevertheless, the studies we examined here fail to provide us with any additional evidence of this sort.

These studies did not find an increased risk of dementia in case of late-life depressive symptoms, as opposed to the first group of studies. The authors' point is generally based upon an absence of significant findings or results that lose statistical significance after correction for certain biasing factors. Some, however, do establish a risk relationship in specific situations, e.g., in combination with sex or *APOE* genotype ([@B49]; [@B43]). Others report an association with depressive episodes earlier in life as opposed to current symptoms ([@B57]; [@B34]). Several studied rather small populations, and their relatively low numbers of incident dementia cases may in itself account for a negative result ([@B34]; [@B9]; [@B11]; [@B43]). This may also be the case for wide confidence intervals \[e.g., in [@B34]), 0.82--6.69\]. Some of these did not find any significant risk factors for dementia, apart from increasing age, which stands in apparent conflict with what is generally accepted in dementia research ([@B8]; [@B50]) and quite possibly suggests insufficient power. We note that one study ([@B43]) reported an increased risk of dementia only for depressive males carrying an *APOE* ϵ4 allele. Lindsay et al. ([@B49]) looked only at syndromal (i.e., clinician-diagnosed) depression, as opposed to most of the other studies that utilized (self-reported) symptom scores. Two studies (41 and 44) report on the same cohort. The population studied in ([@B34]) was analyzed again in ([@B53]), which is category B and supports the prodrome hypothesis ([**Table 3**](#T3){ref-type="table"}). Most population sizes in [**Table 2**](#T2){ref-type="table"} are smaller than those in other groups. In combination with other factors, as mentioned above, we conclude that several of these studies were probably underpowered to detect a connection and do not formally nor decisively contradict the notion that depressive symptoms and dementia are connected.

Considering that both neuropsychiatric illnesses may manifest themselves epidemiologically as hazard increasing, it can be difficult to distinguish between a causal risk factor and prodromal symptom in the years leading up to a diagnosis of dementia---as discussed above. Nevertheless, the authors in this category found support in their findings for the latter hypothesis. Several arguments in favor of this position are advanced by the authors of these studies. These include an increasing symptom burden over time ([@B53]) and no effect of (the length of) episodes occurring earlier in life as opposed to current and recent symptoms ([@B29]; [@B48]). Others note a clear temporal relationship of both illnesses around diagnosis ([@B47]; [@B3]) or a synergistic effect with white matter pathology ([@B73]). Concerning this last element especially, it is posited that in some proportion of elderly patients, depressive symptoms actually represent the organic effect of ongoing pathological processes (cerebrovascular and/or neurodegenerative) on affect-modulating networks in the brain ([@B70]).

One must also consider here the possibility that depressive symptoms could be a reaction to patients' awareness of cognitive decline and thereby frequently manifest during prodromal and early stages of dementia. Several authors, however, reported no clear effect of baseline cognition and emotional symptoms to later dementia ([@B18]; [@B33]; [@B29]; [@B37]; [@B48]; [@B53]; [@B28]), providing a solid argument against this position. Furthermore, other studies have reported that no clear or ubiquitously negative reaction to dementia in recently diagnosed subjects can be demonstrated ([@B17]). We therefore hypothesize that, even though this may occur in everyday clinical situations (e.g., someone worrying about future cognitive decline, possibly due to contact with the dementing illness of a relative), a negative affective response to noticing one's own decline alone cannot explain the association between depressive symptoms and dementia in all patients. Future and ongoing studies like the ABIDE project ([@B71]) will be of help to shed further light upon this association.

These studies propose multiple explanations or more complex associations between depression and dementia. [@B30]) (studying the same cohort as [@B18]) in category B, [**Table 3**](#T3){ref-type="table"}) hypothesized that, while depressive symptoms are indeed cross-sectionally associated with cognitive symptoms, they were unrelated to later cognitive decline, while noting that increasing cognitive symptoms associated with depression likely represent incipient dementia. Kaup et al. ([@B42]) described that increasing severity of depressive symptoms on repeated assessments, rather than a one-time scoring, was associated with increased risk of dementia, thereby lending support to both risk factor and prodromal hypotheses. [@B51]), through multiple interaction models, show that only major depressive episodes (i.e., depression in the strict sense) seem to increase risk of dementia as opposed to milder depressive symptoms whose effect disappears in multivariate analyses.

[@B75]; [@B77]; [@B78]) have published three interesting studies. Their 2003 paper showed that, in a group of 130 elderly religious order members, each increase in depressive symptomatology increased the risk of being diagnosed with AD. However, this did not seem to correlate well with the burden of AD neuropathology at autopsy, leading the authors to conclude that some other mechanism must drive the association between depression and dementia. They confirmed this finding in an expanded cohort of 1,750 people, 600 of whom underwent neuropathological examination, and again in a third paper. They found no support for depression being merely a psychological reaction to incipient cognitive decline but confirmed the association between depressive symptomatology and later dementia. They hypothesized that some mechanism, independent of the postmortem hallmarks of AD (i.e., plaques and tangles), must drive the association between depression and cognitive decline. Exactly what drives this intriguing finding remains to be elucidated in future studies. These should include newer biomarkers, as guided by fundamental scientific insights.

An amyloid-PET-based study has yielded similar results (i.e., showing no clear link with amyloid pathology) when evaluating hippocampal atrophy in a cohort of depressed people and matched controls ([@B21]), even though others have pointed out that amyloid-positive individuals do have a tendency to progressively manifest more neuropsychiatric symptoms ([@B36]; [@B23]). It is clear that further research efforts could and should use the newer antemortem diagnostic techniques (e.g., LP and/or PET) to add to these findings.

Discussion {#s4}
==========

Our systematic literature review yielded no conclusive arguments in support of or contradicting the exact nature of the etiological relationship between depression and dementia. Multiple studies, however, contain convincing arguments for the respective position on this topic (A1, A2, B, C, D) that their authors defend. Some issues raised in the *Results* section of category A2 ("not a risk factor"), however, cast doubt on the power several of these studies to detect connections (or their absence). We deem it unlikely that there should be no connection at all, or that everything can be explained by subjects' emotional responses to incipient decline. We therefore conclude that depressive symptoms may be both a risk factor for and a prodromal symptom to dementia. They may sometimes be coincidental and/or stem from shared risk factors in the elderly. Exactly what mechanism(s) drive(s) this pathophysiological association remain(s) unclear and could not be elucidated by this systematic review. Limitations of our effort in this sense will be discussed in the next section of this article.

Multiple studies were excluded from our main results as they examined the relationship between depressive symptoms and cognitive decline, variously defined ([@B25]; [@B7]; [@B79]; [@B76]; [@B6]; [@B32]; [@B62]). Due to this heterogeneous construct (rather than the binary dementia--no dementia), these studies did not answer our research question. They remain, however, certainly of interest of the broader research area we considered in the *Introduction* section. Since these studies contain useful information for investigators looking into the cognitive effects of depression, they are listed here for further reading. Five of them report an increased risk of cognitive decline among depressed elders ([@B79]; [@B76]; [@B6]; [@B32]; [@B62]), whereas two of them do not ([@B25]; [@B7]).

As we wanted to study the interaction between late-life depression and dementia, studies including a large proportion of subjects younger than 65 years of age were excluded. Indeed, dementia is rare in this age group, and early- versus late-onset depression may differ clinically ([@B35]). As mentioned before ([@B56]), some of these studies suggest that \[severe ([@B66])\] early-life depressive episodes appear to have an "additive" effect on dementia risk, supporting depression as a causal factor or related to the same underlying pathology, such as vascular disease ([@B72]). [@B20]) and [@B41]) reported similar findings, albeit in older populations. These findings may be relevant to our review question and often imply a causal role for depression and depressive symptoms, much like the studies in Table 1. Even though the studies mentioned cannot be included in our systematic review, given our inclusion criteria, we briefly refer to these studies here ([@B24]; [@B41]; [@B20]; [@B66]; [@B72]), as most do appear to support a link between depressive symptoms and dementia.

Neuropsychiatric symptoms in the elderly are common, pervasive, and incapacitating. In the search for validated biomarkers of (later) dementia, simple and cheap interventions, such as a structured mental health assessment or a quick screening tool for depressive symptoms, may complement expensive and/or invasive tools like imaging and laboratory tests in determining individual patients' risk profile. Hopefully, these can in turn lead to tailored risk mitigation strategies for individuals at risk that can be implemented on a large scale. Future research should aim at identifying novel techniques that are able to identify those depressed elders at high risk for "conversion" to dementia. There may be a role to play in unraveling this connection for certain issues raised in the papers we discussed. The effects of gender, genetics, cerebrovascular disease and inflammation, upon the interaction between depressive symptoms and (certain types of) dementia should be studied further using a combination of large datasets and modern technology. We believe that these areas of study may yield clues to understand the actual pathophysiological mechanisms driving the association between mood symptoms and cognitive decline and in turn guide future trials.

We hypothesize that newer diagnostic techniques---*in vivo* biomarkers through CSF analysis, targeted molecular imaging through positron emission tomography techniques, advanced (magnetic resonance) imaging analysis---unavailable during many of the prospective study periods of the cohort studies we cited---may facilitate in this effort in overcoming the shortcomings of existing studies. The studies we included are mainly based on cohorts from years or even decades ago, when much fewer (para) clinical diagnostic tools were available. By increasing diagnostic accuracy and concordance with pathological diagnoses, disease-specific mechanisms may be identified more easily as compared to the more heterogeneous cohorts described above. We theorize that these techniques may facilitate an early identification of those depressed elders at an especially high risk of developing degenerative dementia. Second, future trials should examine whether and which treatments in the depressive elderly---with or without evidence of preclinical or prodromal neurodegeneration---may mitigate their risk of later dementia.

Limitations and Heterogeneity {#s5}
=============================

-Of the Studies Included {#s5_1}
------------------------

It is technically and ethically impossible to conduct a randomized, controlled trial to study the association between depression and dementia. Therefore, conclusions are based on observational studies. This means that the highest levels of evidence quality are not met. This is especially relevant when taking heterogeneity across studies into account in conducting systematic reviews and meta-analyses. We note that most studies are of similar quality when assessed using the NOS (see [**Supplementary Material**](#SM1){ref-type="supplementary-material"}). We therefore deem it unlikely that specific types of systematic bias in study design (apart from some concerns raised over the "negative" studies in Category A2) have influenced the categorization of studies and/or our general conclusions.

Related to the Diagnosis of Dementia {#s5_2}
------------------------------------

Dementia diagnoses were based on Diagnostic and Statistical Manual of Mental Disorders (DSM) (be it III or IV, revised or not) criteria in all but two studies ([@B42]; [@B3]), which relied on healthcare records and coding, prescription of cholinesterase inhibitors, and other "indirect" signs of a dementia diagnosis in their cohorts. AD diagnosis---if evaluated separately---was similarly based on National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria in most studies. Of note, almost no studies included additional "objective" biomarkers of AD or other dementias, which added to the heterogeneity of the investigated populations. The relatively low etiological diagnostic accuracy of non-biomarker-based clinical diagnostic criteria alone does not help this issue ([@B26]). A minority of studies employed DNA analysis---mainly for *APOE* genotyping ([@B49]; [@B37]; [@B43]; [@B64]; [@B55]; [@B53]). While most criteria for "dementia" as such are quite clear, there are of course multiple causes for this clinical syndrome, and several studies do not formally differentiate between AD and other causes of dementia, very probably contributing to less clear results and precluding conclusions about specific types of dementia and their possible association with depressive symptoms. These issues may have influenced study findings and the conclusions of this systematic review.

Depression Measures {#s5_3}
-------------------

It is of interest to researchers and clinicians to differentiate between several elements of the depressive syndrome (anhedonia, low positive affect, motivational symptoms, vegetative or melancholic symptoms,...) to elucidate the role they have in causing clinical overlap between multiple disease states in the elderly: medical illness and pharmacological effects, major depression, apathy, incipient dementia, etc. ([@B35]). Rating scales differ in their focus on/attributing points to these elements of the depressive syndrome.

Fourteen studies used the Centre for Epidemiological Studies--Depression (CES-D) self-rating scale for assessing depressive symptoms at a given moment. Nevertheless, even they differ in the cutoff values used (e.g., 16, 11, 10, or 9 points); two studies use a modified scale, some use different cutoff values for men and women, while others did not. No less than nine other scales and evaluations were used, with or without a "regular" clinical psychiatric assessment of depression (generally based on DSM criteria). Ascertaining past episodes of depression was even harder due to recall bias and a general lack of recognition of multiple depressive symptoms and episodes in the general population ([@B59]). Although some of the included studies examined specific symptom trajectories of depression, most use a one-time screening tool inquiring about symptoms in the last few days or weeks, which is probably inadequate to distinguish true depression from subsyndromal depressive symptoms. This limits strong conclusions about what kind and/or severity of depressive symptoms are specifically related to future dementia and should, therefore, be actively identified and/or treated by clinicians.

Populations {#s5_4}
-----------

Studied populations were relatively heterogeneous across cohorts. Participants' age was similar in most studies, with some studies focusing on the oldest old ([@B57]; [@B74]; [@B58]). While a general female preponderance in studies of the elderly is to be expected and was indeed seen in most studies, some (29 and 47) looked at men only, with one ([@B67]) having an all-women cohort. Most (if not all) of these studies were conducted in the industrialized world. They do, however, contain populations from different continents and multiple ethnic backgrounds in rural as well as urban cohorts. Whether study findings can be extrapolated on a cross-cultural or global scale remains an open question.

Risk Analysis and Prospective Studies {#s5_5}
-------------------------------------

While almost all studies corrected their results (concerning risk of developing dementia) for potentially confounding variables, almost none used an exactly identical list of confounders. Given that depressive symptoms and dementia are both common and have overlapping risk factors (e.g., socioeconomic status), this lack of uniformity across studies further hampers the disentanglement of causal relationships.

As in all epidemiological studies, and especially those in old age, attrition bias (due to loss of follow-up, intercurrent illness, or death) is significant. Furthermore, multiple authors have suggested that dropped-out participants are more likely to suffer from depression and/or dementia ([@B13]), possibly attenuating the risk found in study "survivors." Moreover, several authors have pointed out that people with depressive symptoms have more comorbid medical illnesses and die earlier (which is also true for people with dementia) ([@B2]). We hypothesize that this attrition bias may underestimate some risk relationships and could produce false-negative results.

-Limitations of This Review {#s5_6}
---------------------------

As can be expected from examining the complex association between depressive symptoms and dementia, major methodological differences exist between studies. There are profound and significant differences concerning the populations studied, diagnostic evaluations used, follow-up frequency and duration, corrections for bias, etc. These inconsistencies add to the difficulty of answering our research question (i.e., depression being a cause, effect, both, neither,... of dementia) that is in itself challenging to answer using prospective studies. Grouping studies and data that are this heterogeneous are a major limitation of the existing data. This also complicates hypothetical statistical analyses of data extracted from these studies.

We do not provide here a complete list of excluded studies, did not do the initial searches in duplicate, and cannot exclude any human errors in selection. Since the link between depression and dementia is a hotly debated one, with publications supporting multiple causal hypotheses, we do not think that (positive) publication bias has a major impact on our findings, although we cannot formally exclude this. We did not search all of the available literature databases, although it is unlikely they should have yielded important studies unlisted in Medline (as illustrated by our lack of additional findings in PsycINFO).

Conclusions and Future Perspectives {#s6}
===================================

Despite our clear initial research question, this systematic review did not provide a single answer to the question of how depressive symptoms and later dementia are related. According to our review effort, grouping multiple large studies that provide conflicting results, it remains unclear whether depressive symptoms in the elderly are a risk factor for or a prodromal symptom of dementia. They still may be related mainly through common causal factors, e.g., aging or vascular disease. It seems unlikely that they are not at all related, or only in an indirect way--for example, evidence does not support the hypothesis that a negative emotional response to incipient cognitive symptoms alone can explain the connection between depressive symptoms and dementia.

Several interesting issues raised in some of the studies included, although outside the scope of this review, also deserve further evaluation. These include but are not limited to the role of gender and genetic factors, systemic inflammation and cerebrovascular disease, different etiologies of dementia developed (utilizing recent advances in pathological classification), the nature and severity of symptoms, in modulating the odds of developing dementia in depressive elders.

We deduce from this systematic review that depressive symptoms can be an independent risk factor for as well as a prodromal manifestation of dementia. In some cases, they may both stem from common risk factors such as cerebrovascular disease. In others, they may not have causal connections at all and simply occur together by chance---as two separate yet prevalent neuropsychiatric diseases with overlapping and prevalent risk factors. It remains, on the basis of these findings, challenging to identify those depressed elders at an increased risk of later dementia in clinical practice and, by extension, who would benefit from specific interventions to attenuate this risk.

Therefore, further research is needed to unravel the association between depression and dementia. Preferentially, this research should use a large database to have sufficient statistical power to determine which risk factors--possibly a combination of clinical characteristics and biomarkers, hardly available at all in the studies we examined---increase the risk of conversion to dementia in the depressed elderly. These risk factors should subsequently be validated in prospective, longitudinal clinical studies including elders with and without depressive symptoms in whom clinical, biochemical, and neuropsychological follow-up will decipher which (sub)group later develops cognitive deterioration and dementia. These risk factors can then be incorporated into a clinically useful risk score, of paramount importance for future efforts in the prevention of dementia---and therefore of interest to clinicians, researchers, and patients worldwide.
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